North American Scientific Completes Sale of Non-Therapeutic Product Line
"We have successfully closed this transaction in the expected time frame and we are now focused on the therapeutic areas of our business with our Prospera and ClearPath product lines for local radiation treatment for the prostate and breast cancer patient," said John Rush, President and CEO of North American Scientific. "The proceeds from the sale of this product line will provide the Company with important non-dilutive capital to invest in ongoing operations."
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.